Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer by Jonathan Henricks, Tyler Haddad, Omair Ahmed, Jonathan Schoenhals, Pavnesh Kumar, Ryan Wilson, Jianing Ma, Jing Gennie Wang, Michael Wert, Vincent Esguerra, Ian Bentley, Kai Johnson, Daniel Stover, Sachin R. Jhawar, Margaret Gatti-Mays, Kevin Ho

Subjects: “…Trastuzumab-Deruxtecan…”
Get full text

A Cost-Effective and Robust Cell-Based Bioassay Method for Evaluating the Bioactivity of Trastuzumab-like Antibodies by Pooja Bharali, Subhash Chand, Harish Chander

Subjects: “…trastuzumab…”
Get full text

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre by Anna-Maria Lazaratos, Matthew Dankner, Aalya Hamouda, Soumaya Labidi, Victor Cohen, Lawrence Panasci, Jennifer E. Friedmann, François Patenaude, Cristiano Ferrario, Mark Basik, April A. N. Rose, Parvaneh Fallah

Subjects: “…trastuzumab…”
Get full text

Impact of adjuvant trastuzumab therapy and its discontinuation on cardiac function and mortality in patients with early-stage breast cancer: An analysis based on the Japanese Recei... by Keiko Miyazato, Hiroshi Ohtsu, Akihiko Shimomura, Naohiro Yonemoto, Chikako Shimizu, Kazuhiro Sase, Shinichiro Ueda

Subjects: Get full text

Fluorescence Lifetime Imaging for Quantification of Targeted Drug Delivery in Varying Tumor Microenvironments by Amit Verma, Vikas Pandey, Catherine Sherry, Taylor Humphrey, Christopher James, Kailie Matteson, Jason T. Smith, Alena Rudkouskaya, Xavier Intes, Margarida Barroso

Subjects: Get full text

Prognosis and cardiotoxicity associated to adjuvant trastuzumab for breast cancer: real world study in a public health system by Ana Elisa Ribeiro da Silva Cabello, César Cabello, Susana Oliveira Botelho Ramalho, Otávio Rizzi Coelho, Otávio Rizzi Coelho-Filho, Helymar da Costa Machado, Délio Marques Conde, Luiz Carlos Zeferino

Subjects: Get full text

Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo by Zheng Wang, Yu Liu, Yunxia Xu, Lin Lu, Zhen Zhu, Baojie Lv, Xin Fang, Yao Tang, Jinhua Wang, Yu Cheng, Ying Hu, Junwen Lou, Peican Wu, Chendan Liu, Yanjun Liu, Xin Zeng, Qing Xu

Subjects: Get full text

Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus by Emad Dawoud, Fathi Azribi, Aref Chehal, Shaheenah Dawood, Syed Hammad Tirmazy, Dina Hamza, Hassan Jaafar, Hussam Marashi

Subjects: Get full text

Recognition of HER2 expression in hepatocellular carcinoma and its significance in postoperative tumor recurrence by Ji‐Hua Shi, Wen‐Zhi Guo, Yang Jin, Hua-Peng Zhang, Chun Pang, Jie Li, Pål‐Dag Line, Shui‐Jun Zhang

Subjects: Get full text

Update on Pulmonary Toxicity Induced by New Breast Cancer Treatments by Belluzzi L, Martinelli G, Medici B, Farina A, Martinelli E, Canino F, Caggia F, Molinaro A, Barbolini M, Tamburrano F, Moscetti L, Piacentini F, Dominici M, Omarini C

Subjects: Get full text

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan by Ünal Metin Tokat, Ashkan Adibi, Ashkan Adibi, Esranur Aydın, Şevval Nur Bilgiç, Eylül Özgü, Onur Tutar, Mutlu Demiray

Subjects: Get full text

Investigation of <i>ITGB3</i> Heterogeneity to Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer by Asiye Busra Boz Er

Subjects: Get full text